The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no ...

The following is a summary of "Prognostic value of non-invasive right ventricle-pulmonary artery coupling in patients with ...

Foresee Pharma begins patient dosing in phase 2 WINDWARD study of mirivadelgat to treat pulmonary hypertension-associated interstitial lung disease: Taipei, Taiwan Friday, May 16, ...

Earlier this afternoon, Gossamer Bio issued a press release announcing its first-quarter 2025 financial results and provided a corporate update. Please note that certain information discussed on the ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...

Weibo Corporation ("Weibo" or the "Company") , a leading social media in China, today announced that the following proposed resolutions submitted for shareholder approval have been adopted at its 2025 ...

As mid-May unfolds, crypto market sentiment continues to rise. While major assets trend steadily upward, capital is beginning to rotate into fundamentally solid altcoins. In this edition of HTX ...

Quince Therapeutics advances Ataxia-Telangiectasia treatment with innovative AIDE platform, insider support, and NEAT Phase 3 ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced the risk of severe exacerbations by 47% compared to albuterol, the ...

Tom Nolan reviews this week’s research There’s certainly a gap in the market for an effective third or fourth line antihypertensive. A trial of lorundrostat, an aldosterone synthase inhibitor, found a ...